Scientists on Science

Advances in Immunotherapy

A talk by Drew M. Pardoll, MD, PhD

Dr. Pardoll is the scientific founder and board observer at Amplimmune Inc. (formerly Amplimmune Immunology). Pardoll cofounded Jounce Therapeutics Inc. in 2012. He serves as a board observer at Aduro BioTech Inc. He serves as chairman of Scientific Advisory Board at Aduro BioTech Inc. He served as chairman of the Scientific Advisory Board at Cerus Corporation since May 2004. He serves as member of Scientific Advisory Board of Compugen Ltd., Immunexcite Inc., and Jennerex. He serves as a member of Scientific Advisory Council at Cancer Research Institute, Inc. He has been member of advisory board at ISA Pharmaceuticals B.V. since Oct. 15, 2013. He serves as a member of Scientific and Medical Advisory Board at Mojave Therapeutics Inc. Prof. Pardoll serves as director of the Cancer Immunology Program in the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins. He served as a Director at Amplimmune Inc. He has served on the editorial boards of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard Dana-Farber Cancer Center, Global Medical Products Corporation, Genencor Corporation, CellGenesys Corporation, the American Association of Clinical Oncology and the American Association of Cancer Research. He served as a director at Aduro BioTech Inc. He served as a member of Vaccine Scientific Advisory Board at Cerus Corporation since May 2004.

For the past two decades, Pardoll has studied molecular aspects of immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. Pardoll made seminal advances in immunology, including the discovery of new types of immune cells and regulatory mechanisms. He was the first to propose blockade of PD-1 for cancer therapy, and his program led the clinical development of the first anti-PD-1 antibody. Pardoll is an internationally recognized authority in cancer immunology and immunotherapy. He is noted for demonstrating the central role of GM-CSF in stimulating dendritic cells in vivo. In addition, he is a co-inventor of cytokine-gene-transduced tumor vaccines. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines.

Pardoll has published over 200 papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. Pardoll completed his medical and doctorate degrees, medical residency, and oncology fellowship at Johns Hopkins University.

Listen to Dr. Pardoll's talk on "Advances in Immunotherapy."